Page 117«..1020..116117118119..130140..»

Stem Cell Research: Argumentative Essay – Free Essay Example – Edubirdie

Posted: March 4, 2023 at 12:10 am

What if there was a chance of curing degenerative diseases such as Parkinsons and Alzheimers? Everyone should be in favor of ending the suffering of the thousands of people who have these diseases and their families that have to be brought in by such a curse. These diseases and a surplus more can be cured with the potential results of stem cell research. Embryotic stem cells are undifferentiated cells in the womb. The factor of being undifferentiated is crucial to embryotic, and in disease cures, tissue development. Through each stage of fetal development, the embryo will have its stem cells differentiated into different cells. Examples will include muscle, neural, intestinal, cardiac, liver, and blood cells. Research using these undifferentiated cells requires the destruction of an embryo, making the practice an immoral undertone. Some will argue that the embryos in the womb do not deserve disrespect, based on the idea of not harming any form of life. While the other side, in favor of stem cell research, will overlook such unethicality for the benefit of future cures that could save many other out-of-womb lives. Nations around the world should fund stem cell research due to the possible cures in the future.

Stem cells are our baseline for development in the womb and can build 260 different kinds of cells in the human body. Sadly, this research involves using and destroying embryos and possible lives, to save lives and make them easier. Using embryonic cells can result in negative outcomes, and has been greatly associated with causing brain tumors and cancer. In addition to governmental reinforcements, many limitations, including immune rejection which can cause death and tumor possibility, are factors that convince the public that the research should not be advanced. Others can see this research as playing god. As described by Peter Lachmann, playing god carries with it the proposition that there is knowledge that may be too dangerous for the mankind to know (2). Later in his work, Lachmann digs up an ancient code of conduct still used today, the Hippocratic oath. The Hippocratic oath swears that by your own hands every Ph.D. shall not knowingly cause harm to another life. Reaching back to morals, the scientists and doctors involved are breaking the Hippocratic oath, by tearing apart the fetuses in the womb, whether natural or lab-made.

On the other hand, the scientists who see eye-to-eye with stem cell research are currently restricted by the amount of federal funding and embryonic cells available for research. The reason for this is the fact that everyone sees that any products and medication put forth from this medical boom would be far too expensive. Some scientists worry that if strict regulations of stem cell research continue, private companies may bypass the standards put in place by the National Institute of Health and conduct unregulated research. If the United States wishes to remain a premiere country in biomedical research and maintain order and control of embryonic research being performed, action must be taken to address this issue.

Save your time!We can take care of your essay

Barack Obama says that we have been given the capacity and will to pursue this research and the humanity and conscience to do so responsibly. Governments around the globe have passed legislation to regulate stem cell research. In the United States, laws prohibit the creation of embryos for research purposes. Scientists instead receive leftover embryos from fertility clinics with consent from donors. Most people agree that these guidelines are appropriate. Disagreements surface, however, when political parties debate about how to fund stem cell research. The federal government allocates billions of dollars each year to biomedical research. Legislators have had the unique challenge of encouraging advances in science and medicine while preserving respect for life. U.S. President Bush, for example, limited federal funding to a study of 70 or so hES cell lines back in 2001. While this did slow the destruction of human embryos, many believe the restrictions set back the progress of stem cell research. President Obama overturned Bushs stem cell policy in 2009 to expand the number of stem cell lines available to researchers.

Despite the moral issues, these cells show an overpoweringly higher possibility to heal illness. Embryonic stem cell study contributes drastically to the systematic grasp of stem cells. An imperative factor in stem cell therapy treatments is the ability to use the patients own stem cells to generate the most effective medical therapies. Such therapies will not be redundant to the bodys immune mechanism. New therapies employing adult stem cells like those initiated in bone marrow and teeth are important for medicinal research. Pro research advancement researchers hope that by controlling stem cells in the lab, they can be employed to treat Parkinsons disease, heart disease, diabetes, and some disorders (Hug 114). The main clinical supply is the aborted fetus and unexploited embryos presently housed in frozen stores at IVF facilities. An advanced stem cell line originates from a solitary embryo, rotating into a collection of cells that reproduces nonstop. Even if one cannot point to a precise separating line in human growth when personhood is acquired, it may be debated that every time the transition happens, early pre-implantation period embryos do not encompass the physiological, psychological, expressive, or intellectual characteristics that are associated with a persons identity. It, consequently, follows that if the embryo does not accomplish the principle of personhood, it does not contain any happiness to be confined and thus may be employed instrumentally for the advantage of human beings. The supporters of embryonic stem cell advancement argue about the point that it will assist to alleviate some agonies.

Overall, though the destruction of a life is typically seen to be unethical, the moral status of an embryo in the blastocyst stage is unclear and therefore cannot be equated to the moral status of an adult human being. Also, ethical sources of embryonic stem cells exist that do not take the life of future beings (i.e. unwanted frozen embryos produced via in vitro fertilization, donated egg cells fertilized in a laboratory). For these reasons, in combination with the possibility of reducing suffering for future beings, embryonic stem cell research is ethical under certain circumstances. As long as the stem cells are isolated in a manner that does not harm an embryo with the plan of developing into an adult human, the subsequent research is ethically justified. With this in mind, embryonic stem cell research should receive greater government funding so that continued progress can be made.

The debate over embryonic stem cell research is a scientific, moral, and political issue. Embryonic stem cells, hold important value for scientific researchers in search of cures for untreatable diseases, medicine to regenerate an assortment of tissues, or a better understanding of early human development. As a consequence, if they are stopped, many people will keep on suffering from terrible diseases that could be cured. In fact, the throbbing and damaging consequences might be alleviated by technologies and therapies attained from embryonic stem cell studies.

More:
Stem Cell Research: Argumentative Essay - Free Essay Example - Edubirdie

Posted in Stem Cell Research | Comments Off on Stem Cell Research: Argumentative Essay – Free Essay Example – Edubirdie

Mendus AB: Mendus announces request for conversion of convertible bonds by Negma Group

Posted: February 24, 2023 at 12:14 am

Mendus AB (“Mendus” publ; IMMU.ST), a biopharmaceutical company focused on immunotherapies addressing tumor recurrence, today announced that Negma Group (“Negma”) has by notice to Mendus requested the conversion of convertible bonds that have been issued to Negma in accordance with the financing agreement announced by Mendus through press releases on 26 August and 26 October 2022.

Read the original post:
Mendus AB: Mendus announces request for conversion of convertible bonds by Negma Group

Posted in Global News Feed | Comments Off on Mendus AB: Mendus announces request for conversion of convertible bonds by Negma Group

binx health to Present at the Upcoming BioCapital Europe 2023 Conference

Posted: February 24, 2023 at 12:14 am

BOSTON, Feb. 23, 2023 (GLOBE NEWSWIRE) -- February 23, 2023 (GLOBENEWSWIRE) – binx health, a healthcare technology and diagnostics company focused on making routine testing convenient, announced today that Jeff Luber, Chief Executive Officer, will present at the BioCapital Europe 2023, a life sciences investment conference taking place on March 9, 2023, in Amsterdam, the Netherlands. The presentation will feature the binx io, the first ever FDA-cleared, CLIA-waived, point-of-care chlamydia and gonorrhea test for males and females, providing central lab performance results in about thirty minutes. Additional conference and presentation details are as follows:

Go here to read the rest:
binx health to Present at the Upcoming BioCapital Europe 2023 Conference

Posted in Global News Feed | Comments Off on binx health to Present at the Upcoming BioCapital Europe 2023 Conference

Press Release: FDA approves once-weekly ALTUVIIIO™, a new class of factor VIII therapy for hemophilia A that offers significant bleed protection

Posted: February 24, 2023 at 12:14 am

FDA approves once-weekly ALTUVIIIO™, a new class of factor VIII therapy for hemophilia A that offers significant bleed protection

See the article here:
Press Release: FDA approves once-weekly ALTUVIIIO™, a new class of factor VIII therapy for hemophilia A that offers significant bleed protection

Posted in Global News Feed | Comments Off on Press Release: FDA approves once-weekly ALTUVIIIO™, a new class of factor VIII therapy for hemophilia A that offers significant bleed protection

Collegium Reports Fourth Quarter and Full-Year 2022 Financial Results

Posted: February 24, 2023 at 12:14 am

– Generated Record Quarterly and Full-Year Net Revenue of $129.6 and $463.9 Million –

Link:
Collegium Reports Fourth Quarter and Full-Year 2022 Financial Results

Posted in Global News Feed | Comments Off on Collegium Reports Fourth Quarter and Full-Year 2022 Financial Results

Travere Therapeutics Reports Fourth Quarter and Full Year 2022 Financial Results

Posted: February 24, 2023 at 12:14 am

Recently received U.S. FDA accelerated approval of FILSPARI™ (sparsentan), the first and only non-immunosuppressive therapy for the reduction of proteinuria in IgA nephropathy (IgAN)

Here is the original post:
Travere Therapeutics Reports Fourth Quarter and Full Year 2022 Financial Results

Posted in Global News Feed | Comments Off on Travere Therapeutics Reports Fourth Quarter and Full Year 2022 Financial Results

ARS Pharmaceuticals Announces Presentation of Data Supporting neffy (epinephrine nasal spray) and Real-World Burden of Needle Injectors

Posted: February 24, 2023 at 12:14 am

Data to be Presented in Five Poster Presentations at the 2023 American Academy of Allergy, Asthma and Immunology Annual Meeting

Read the original here:
ARS Pharmaceuticals Announces Presentation of Data Supporting neffy (epinephrine nasal spray) and Real-World Burden of Needle Injectors

Posted in Global News Feed | Comments Off on ARS Pharmaceuticals Announces Presentation of Data Supporting neffy (epinephrine nasal spray) and Real-World Burden of Needle Injectors

Galapagos announces full year 2022 results and outlook for 2023

Posted: February 24, 2023 at 12:14 am

Key 2022 and post-period events

Originally posted here:
Galapagos announces full year 2022 results and outlook for 2023

Posted in Global News Feed | Comments Off on Galapagos announces full year 2022 results and outlook for 2023

Kura Oncology Reports Fourth Quarter and Full Year 2022 Financial Results

Posted: February 24, 2023 at 12:14 am

– Phase 1 data for ziftomenib highlighted by 30% CR rate among 20 patients with NPM1-mutant AML treated at recommended Phase 2 dose –

Read the original post:
Kura Oncology Reports Fourth Quarter and Full Year 2022 Financial Results

Posted in Global News Feed | Comments Off on Kura Oncology Reports Fourth Quarter and Full Year 2022 Financial Results

Enochian BioSciences Announces Receipt of Notice from Nasdaq Regarding Delayed Filing of Form 10-Q for the Period Ended December 31, 2022

Posted: February 24, 2023 at 12:14 am

LOS ANGELES, Feb. 23, 2023 (GLOBE NEWSWIRE) -- (NASDAQ: ENOB) -- On February 16, 2023, Enochian BioSciences Inc. (the "Company") received a notice (the "Notice") from The Nasdaq Stock Market LLC ("Nasdaq") stating that because the Company has not yet filed its Form 10-Q for the period ended December 31, 2022 (the "Form 10-Q"), the Company remains in non-compliance with Nasdaq Listing Rule 5250(c)(1), which requires listed companies to timely file all required periodic financial reports with the Securities and Exchange Commission (the "SEC"). As previously disclosed on Form 8-Ks filed with the Securities and Exchange Commission, on October 17, 2022 and November 23, 2022, respectively, the Company received notices from Nasdaq indicating that as a result of not having timely filed its Annual Report on Form 10-K for the period ended June 30, 2022 (the "Form 10-K") and its Quarterly Report on Form 10-Q for the period ended September 30, 2022, the Company was not in compliance with Nasdaq Listing Rule 5250(c)(1).

Read more from the original source:
Enochian BioSciences Announces Receipt of Notice from Nasdaq Regarding Delayed Filing of Form 10-Q for the Period Ended December 31, 2022

Posted in Global News Feed | Comments Off on Enochian BioSciences Announces Receipt of Notice from Nasdaq Regarding Delayed Filing of Form 10-Q for the Period Ended December 31, 2022

Page 117«..1020..116117118119..130140..»